1056016-18-2

Basic information

• Product Name: (R)-C&R8
• Synonyms: (2R)-2-[[9-(1-methylethyl)-6-[[[3-(2-pyridinyl)phenyl]methyl]amino]-9H-purin-2-yl]amino]-1-Butanol;(R)-2-((9-Isopropyl-6-((3-(pyridin-2-yl)benzyl)-amino)-9H-purin-2-yl)amino)butan-1-ol
• CAS NO: 1056016-18-2
• Molecular Formula: C₂₄H₂₉N₇O
• Molecular Weight: 431.53336
• Mol File: 1056016-18-2.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-C&R8(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-C&R8(1056016-18-2)
• EPA Substance Registry System: (R)-C&R8(1056016-18-2)

Safety Data

• Hazardous Substances Data: 1056016-18-2(Hazardous Substances Data)

Usage

General Description

(R)-C&R8 is a chiral ligand that is commonly used in organic synthesis reactions. It is known for its ability to catalyze various asymmetric reactions, including the addition of organometallic reagents to carbonyl compounds and the formation of carbon-carbon bonds. (R)-C&R8 is also utilized in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. It is a highly effective and versatile catalyst that has found widespread use in the production of enantiomerically pure compounds. Its unique structure and reactivity make it an important tool in the field of asymmetric synthesis.

Upstream product

• 5856-63-3 (2R)-2-aminobutan-1-ol 
• 1056016-65-9 2-chloro-6-[3-(2-pyridyl)phenylmethylamino]-9-iso-propylpurine 

Relevant articles and documents

Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1

Cyclin-dependent kinases (CDKs) and casein kinases 1 (CK1) are involved in the two key molecular features of Alzheimer's disease, production of amyloid-β peptides (extracellular plaques) and hyper-phosphorylation of Tau (intracellular neurofibrillary tangles). A series of 2,6,9-trisubstituted purines, structurally related to the CDK inhibitor roscovitine, have been synthesized. They mainly differ by the substituent on the C-6 position. These compounds were screened for kinase inhibitory activities and antiproliferative effects. Several biaryl derivatives displayed potent inhibition of both CDKs and CK1. In particular, derivative 13a was a potent inhibitor of CDK1/cyclin B (IC50: 220 nM), CDK5/p25 (IC50: 80 nM), and CK1 (IC 50: 14 nM). Modeling of these molecules into the ATP-binding pocket of CK1δ provided a rationale for the increased selectivity toward this kinase. 13a was able to prevent the CK1-dependent production of amyloid-β in a cell model. CDK/CK1 dual-specificity inhibitors may have important applications in Alzheimer's disease and cancers.